Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
SSGJ-611-PED-AD-Ib/II-01
Phase 2 small_molecule active
Quick answer
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) for Dermatitis, Atopic is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sunshine Biopharma
- Indication
- Dermatitis, Atopic
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active